2 drug(s) with this reaction
671 total reports
Nephrogenic Systemic Fibrosis has been reported as an adverse reaction across 2 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 671 adverse event reports mention nephrogenic systemic fibrosis in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with nephrogenic systemic fibrosis, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have nephrogenic systemic fibrosis listed in their FDA adverse event reports, sorted by report count:
In addition to nephrogenic systemic fibrosis, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
2 drug(s) manufactured by Amgen Inc have nephrogenic systemic fibrosis listed in their FDA adverse event reports: EPOETIN ALFA, CINACALCET HYDROCHLORIDE.
There are a combined 671 reports of nephrogenic systemic fibrosis across 2 Amgen Inc drug(s) in the FDA adverse event database.